Option Chain

Beam Therapeutics Inc

BEAMNASDAQ · USD

26.41USD+0.54 (+2.09%)

227

Beam Therapeutics Inc (BEAM) Option Chain

Beam Therapeutics Inc trades at $26.41, up 2.09%, with an IV Rank of 58.53%. This is average versus the past year, and the company carries a market cap of $2,677M in the Biotechnology industry. On the Nov 20, 2026 chain, the at the money $26.00 strike shows calls at $1.30 / $3.00 and puts at $1.00 / $3.10, both carrying about $1.89 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $30.00 calls, at 28 contracts, and the $23.00 puts, at 6, as of Nov 5, 2026.

Tracking the BEAM option chain helps you see every strike and expiry on Beam Therapeutics Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of BEAM options activity at a glance. Use our scanner to monitor the BEAM option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For BEAM stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where BEAM options are being actively traded, and where they are not.

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders.

CALLs									PUTs
Prob. OTM %	Open Interest	Volume	Extrinsic Value	Intrinsic Value	Bid	Ask	Strike	Moneyness %	Bid	Ask	Intrinsic Value	Extrinsic Value	Volume	Open Interest	Prob. OTM %
36.78	316	0	0.54	2.41	1.00	4.90	24.00	-7.23	—	1.80	0.00	1.80	1	68	63.22
45.62	378	0	1.54	1.41	1.20	4.70	25.00	-3.36	0.95	1.60	0.00	1.28	2	135	54.38
54.32	404	1	1.74	0.41	1.30	3.00	26.00	+0.50	1.00	3.10	0.00	2.05	2	68	45.68
62.51	157	4	1.30	0.00	0.95	1.65	27.00	+4.37	—	4.90	0.59	4.31	0	10	37.49
69.91	584	5	0.80	0.00	0.30	1.30	28.00	+8.23	0.80	4.90	1.59	1.26	0	317	30.09

As of Nov 5, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

IndustryBiotechnology
SectorHealthcare
IV Rank58.53% Moderate
Market cap (M$)2,677
52 weeks high-32.38%
52 weeks low27.88%
Analyst recommendationStrong Buy
1.25
Target price$48.71
83.64% above the current stock price
Dividend—
Payout ratio—
Earnings date2026-11-03
P/E—
Future P/E—
EPS (ttm)-1.04
EPS growth next 5 years—

As of Nov 5, 2026

Browse all Option Chain tickers